Serum antioxidant activity after myocardial infarction
total antioxidant activity (TAA) and the 'antioxidant gap' after myocardial infarction. I They reported that whereas no significant changes were observed in serum total antioxidant activity, a decline in the 'antioxidant gap' after myocardial infarction was associated with a significantly higher mortality. We would like to comment on the validity of their method of derivation of the 'antioxidant gap'.
To calculate the 'antioxidant gap', for each serum sample Miller et al. subtracted from TAA, the activity ascribable to albumin and uric acid. This involved measuring the serum concentrations of albumin and urate and multiplying these values by previously derived conversion factors of 0·69 per mmol/L for albumin and 1·0 per mmol/L for urate.?
The contribution made by albumin to TAA was also recently investigated in our laboratory using a Centrifree Micropartition System (Amicon) which retained proteins of molecular weight > 30 000. TAA was measured in serum samples before and after filtration. The albumin concentrations in serum samples pre and post-filtration were also measured. Furthermore, serial dilutions of albumin (Sigma) were prepared and analysed directly for antioxidant activity. Using both approaches, we calculated that the albumin contribution to the TAA was 0·90 per rnrnol/L, As such, our
Letters 333 results indicate that the conversion factor for albumin used by Miller et al. is an underestimate and that albumin or albumin complexes make a larger contribution to antioxidant activity than previously appreciated. It follows, therefore, that the calculation of the 'antioxidant gap' may be erroneous. Our results for uric acid were in agreement with the figure quoted by Miller et al. Furthermore, irrespective of the above potential discrepancy, it may be wholly inaccurate to assume that the in vivo antioxidative capacity of albumin remains constant at all times. Albumin is a major transport protein in the blood, and there occurs continuous fluctuations in the degree of binding of different compounds to its binding sites, e.g. during stress and in disease situations, all of which may alter its antioxidative capacity.
Therefore, we suggest that the discrepancy found between reported 1 and our experimental findings of the contribution from albumin/ albumin complexes to the total antioxidant activity needs to be investigated further, especially if the concept of antioxidant gap is to have any clinical value.
